Genmab — Januar 2017
-
https://play.borsen.dk/klip/5873e11045628ff8171f7f96 Michael Friis er positiv
-
Celgene's opjustering af Rev-salget er nok ikke kun pga forventet succes i kombi med dara i 2.+linje; men nok så meget at Rev bliver standard of care i 1. linje - som det fremgik af pre-ASH-symposiet. Der går jo lidt tid endnu inden dara skal forsøge sig helt fremme.
-
Enig Bulder.
-
60-70 mio herfra, andre der er meget højere, men det er nok ret realistisk
-
Det er lige en kommentar til snakken igår omkring Darzalex og solide tumorer. @ Fantomas: Ang behandling af solide tumorer med antistoffer, så er dette allerede en succes ved brystkræft. Så det kan ikke passe at antistofferne ikke kan bruges til behandling af solide tumorer. Solide tumorer skal også have næring via blodet, og får cancercellerne ikke næring dør de. Så kommer der antistoffer i blodet, leveres de også til cancercellerne.
-
Ved ikke mere Bulder, men "a large Phase III trial of panobinostat, a new type of myeloma drug called a HDAC inhibitor, were reported. Panobinostat is likely to be the next new agent to be approved by the FDA for relapsed/refractory multiple myeloma. This study evaluated panobinostat in combination with Velcade-dex and showed significantly improved outcomes as compared to Velcade-dex alone". http://multiplemyelomablog.com/2014/06/asco-news-panobinostat-sar650984-and-daratumumab.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind